| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.675 | 0.004 | 0.675 | Vanilloid 1 antagonist | 0.665 0.004 DBMET02571 | ||
| 0.539 | 0.004 | 0.539 | Phosphatidylinositol 3-kinase gamma inhibitor | 0.425 0.004 DBMET02571 | ||
| 0.524 | 0.043 | 0.524 | Analgesic | 0.518 0.044 DBMET02571 | ||
| 0.443 | 0.004 | 0.443 | Phosphatidylinositol 3-kinase beta inhibitor | 0.306 0.004 DBMET02571 | ||
| 0.427 | 0.004 | 0.427 | Vanilloid antagonist | 0.387 0.005 DBMET02571 | ||
| 0.412 | 0.005 | 0.412 | Phosphatidylinositol kinase inhibitor | 0.293 0.005 DBMET02571 | ||
| 0.325 | 0.005 | 0.325 | Phosphatidylinositol 3-kinase delta inhibitor | 0.211 0.007 DBMET02571 | ||
| 0.226 | 0.004 | 0.239 | CC chemokine receptor 2B antagonist | 0.239 0.004 DBMET02571 | DBMET02571 | |
| 0.216 | 0.007 | 0.216 | Phosphatidylinositol 3-kinase alpha inhibitor | 0.145 0.011 DBMET02571 | ||
| 0.264 | 0.08 | 0.264 | Ca(v)3.3 blocker | 0.221 0.15 DBMET02571 | ||
| 0.313 | 0.146 | 0.313 | Calcium channel L-type activator | |||
| 0.215 | 0.073 | 0.215 | MAP kinase kinase 2 inhibitor | |||
| 0.271 | 0.138 | 0.271 | Antiobesity | 0.263 0.145 DBMET02571 | ||
| 0.207 | 0.103 | 0.207 | MAP kinase kinase 3 inhibitor | |||
| 0.226 | 0.129 | 0.226 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | |||
| 0.095 | 0.01 | 0.095 | Cyclin H inhibitor | 0.094 0.01 DBMET02571 | ||
| 0.144 | 0.064 | 0.144 | RET inhibitor | |||
| 0.074 | 0.01 | 0.074 | CDK7/cyclin H inhibitor | 0.069 0.011 DBMET02571 | ||
| 0.132 | 0.074 | 0.132 | Cyclin-dependent kinase 7 inhibitor | |||
| 0.116 | 0.061 | 0.116 | CDK3/cyclin E inhibitor | 0.11 0.07 DBMET02571 | ||
| 0.047 | 0.01 | 0.087 | Diacylglycerol O-acyltransferase 1 inhibitor | 0.087 0.005 DBMET02571 | DBMET02571 | |
| 0.049 | 0.016 | 0.049 | Glutamate (mGluR group II) agonist | 0.048 0.016 DBMET02571 | ||
| 0.069 | 0.037 | 0.069 | Glutamate (mGluR) agonist | 0.067 0.039 DBMET02571 | ||
| 0.065 | 0.035 | 0.065 | CDK9/cyclin T1 inhibitor | 0.055 0.046 DBMET02571 | ||
| 0.044 | 0.016 | 0.044 | Glutamate (mGluR2) agonist | 0.041 0.017 DBMET02571 | ||
| 0.074 | 0.05 | 0.078 | Histone deacetylase stimulant | 0.078 0.046 DBMET02571 | DBMET02571 | |
| 0.074 | 0.05 | 0.078 | Histone deacetylase SIRT1 stimulant | 0.078 0.046 DBMET02571 | DBMET02571 | |
| 0.093 | 0.07 | 0.093 | Chemokine receptor antagonist | 0.084 0.082 DBMET02571 | ||
| 0.19 | 0.172 | 0.19 | Nootropic | 0.187 0.176 DBMET02571 | ||
| 0.065 | 0.054 | 0.065 | CDK1/cyclin B1 inhibitor | |||
| 0.256 | 0.26 | 0.328 | Antiinflammatory | 0.328 0.19 DBMET02571 | DBMET02571 | |
| 0.118 | 0.13 | 0.13 | CC chemokine 6 receptor antagonist | 0.13 0.072 DBMET02571 | DBMET02571 | |
| 0.04 | 0.111 | 0.074 | Glutamate receptor agonist | 0.074 0.059 DBMET02571 | DBMET02571 | |
| 0.024 | 0.136 | 0.06 | Diacylglycerol O-acyltransferase inhibitor | 0.06 0.026 DBMET02571 | DBMET02571 | |
| 0.051 | 0.27 | 0.116 | Neurotrophic factor | 0.116 0.101 DBMET02571 | DBMET02571 | |
| 0.019 | 0.273 | 0.053 | Angiotensin-converting enzyme inhibitor | 0.053 0.042 DBMET02571 | DBMET02571 | |
| 0.132 | 0.398 | 0.238 | Cyclophilin D inhibitor | 0.238 0.226 DBMET02571 | DBMET02571 | |
| 0.012 | 0.599 | 0.037 | Glutamate (mGluR8) antagonist | 0.037 0.022 DBMET02571 | DBMET02571 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |